JNJ - Johnson & Johnson
| Previous Close | 158.32 |
| Open | 159.58 |
| Bid | 157.89 x 800 |
| Ask | 157.92 x 900 |
| Day's Range | 157.40 - 159.61 |
| 52 Week Range | 150.11 - 183.35 |
| Volume | |
| Avg. Volume | 7,245,549 |
| Market Cap | 410.339B |
| Beta (5Y Monthly) | 0.53 |
| PE Ratio (TTM) | 33.10 |
| EPS (TTM) | 4.77 |
| Earnings Date | Jul 20, 2023 |
| Forward Dividend & Yield | 4.76 (3.01%) |
| Ex-Dividend Date | May 22, 2023 |
| 1y Target Est | 179.71 |
BloombergTylenol Maker Kenvue Goes From Sure Bet to Question Mark After Year’s Biggest IPO
(Bloomberg) -- Kenvue Inc. looked like a winner following its May spinoff from Johnson & Johnson in the year’s biggest IPO. But just a few weeks after the stock’s initial surge, Wall Street is urging investors to avoid the shares.Most Read from BloombergUkraine Dam Blast Blamed on Russia Tips War Into New PhasePGA Tour Bows to Saudi Rival in Shock Combination With LIV GolfUS Crypto Crackdown Reaches Fever Pitch as SEC Sues CoinbaseApple Headset Looks Sleek in Person But Battery Pack Stands OutAp
ZacksJohnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
Johnson & Johnson (JNJ) closed at $158.32 in the latest trading session, marking a +0.86% move from the prior day.
ReutersAnalysis-Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast
Johnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the drug a larger contributor to J&J’s 2024 and 2025 sales than Wall Street is forecasting. Stelara, introduced in 2009, has been J&J’s top-selling drug since 2019, with sales reaching $9.7 billion in 2022. Its patents begin to expire this year, opening the door to a cheaper biosimilar entering the market, and raising expectations that the company would need to lower the $13,000 per month price of Stelara.
Motley Fool2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip
Dividend Kings are among the most steady corporations on the market. While many businesses don't even last a decade, these companies have survived and thrived and raised their payouts for at least 50 consecutive years to become a member of this elite group. Case in point: Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) are two members of this prominent clique that have lagged the market recently, partly due to company-specific concerns.
Motley Fool1 Ultra-Elite Dividend Stock to Buy Hand Over Fist in June
Johnson & Johnson (NYSE: JNJ) is one of the best dividend stocks on the planet. The healthcare behemoth has increased its dividend each year for over six decades, putting it in the super-elite class of Dividend Kings. The company currently offers a roughly 3% dividend yield, which is almost double that of an S&P 500 Index Fund (recently around 1.6%).
Motley Fool2 Warren Buffett Stocks to Buy in June and Hold Forever
These time-tested businesses produce reliable cash flows that they're committed to sharing with investors.
Motley FoolThe Little-Known Secret to Beating the S&P 500
If you can't beat the S&P 500 by picking individual stocks, owning an S&P 500 index fund and at least earning market returns is a smart move. Not just any dividend-paying stocks, mind you, but those that can grow their dividend payments consistently. Hartford Funds and Ned Davis Research have been tracking the average annual total returns of companies in the S&P 500 by dividend policy.
Simply Wall St.With 65% ownership, Johnson & Johnson (NYSE:JNJ) boasts of strong institutional backing
Key Insights Significantly high institutional ownership implies Johnson & Johnson's stock price is sensitive to their...
Motley FoolTwo Dow Stocks to Buy in June and Hold for the Next Decade
These two stocks look like the best options among the Dow Jones Industrial Average's 30 components right now.
ZacksLAVA (LVTX) Up on J&J's (JNJ) Cancer Study Candidate Selection
LAVA's (LVTX) shares soar as partner J&J (JNJ) selects a lead candidate for development in clinical studies for cancer.
Motley Fool3 High-Quality Dividend Stocks Yielding 3% to Buy in June
Many high-quality dividend stocks currently yield around 3%, nearly double that of the S&P 500. American Tower's dividend yield is currently over 3%, a historically high rate for the data-infrastructure real estate investment trust (REIT). The company has an exceptional track record of paying dividends.
- Reuters
UPDATE 1-J&J secures dismissal of whistleblower case over misuse of confidential info
A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.
ReutersJ&J secures dismissal of whistleblower case over misuse of confidential info
A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.
- Reuters
REFILE-J&J secures dismissal of whistleblower case over misuse of confidential info
A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.
Motley FoolIs It Too Early to Invest In Nano-X Imaging?
It could take years before Nano-X proves there's strong demand for its devices, and even longer to reach profitability.
Motley Fool2 Dow Stocks to Buy More of in June
The Dow Jones Industrial Average consists of 30 of the most established businesses in the world. Thus, it shouldn't be a surprise to learn that many of the components that belong to this index have decades of dividend growth to their credit. Here are two Dow Jones stocks with more than a century of dividend growth between them to consider buying this month.
Motley Fool3 Reliable Dividend Growth Stocks to Buy Hand Over Fist in June
Adding these well-respected dividend payers to your portfolio could give you a stream of passive income that grows throughout your retirement years.
Motley Fool3 Warren Buffett Stocks That Are Screaming Buys in June
Based on a 58-year track record as CEO of Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B), it's safe to say Warren Buffett knows a thing or two about investing. As of this past weekend, he'd overseen a greater than 3,900,000% return in his company's Class A shares (BRK.A) since taking the reins at Berkshire. What follows are three Warren Buffett stocks that stand out as screaming buys in June.
ZacksZacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
- Reuters
UPDATE 1-J&J faces new trial over talc cancer claims, amid settlement push
Johnson & Johnson on Wednesday faced the first trial in almost two years over claims that asbestos in its baby powder and other talc products causes cancer, as it seeks to settle thousands of similar cases in bankruptcy court. Emory Hernandez, 24, says he developed mesothelioma, a deadly cancer, in the tissue around his heart as a result of exposure to J&J's talc products beginning when he was a baby.
BloombergObesity Shot Frenzy Makes Eli Lilly World’s Most Valuable Drugmaker
(Bloomberg) -- Eli Lilly & Co.’s third straight month of gains has helped it become the largest pharmaceutical company in the world by market value, surpassing Johnson & Johnson.
ReutersJ&J faces new trial over talc cancer claims, amid settlement push
(Reuters) -Johnson & Johnson on Wednesday faced the first trial in almost two years over claims that asbestos in its baby powder and other talc products causes cancer, as it seeks to settle thousands of similar cases in bankruptcy court. Emory Hernandez, 24, says he developed mesothelioma, a deadly cancer, in the tissue around his heart as a result of exposure to J&J's talc products beginning when he was a baby.
ZacksBristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
Zacks5 Large Drug Stocks to Watch From a Thriving Industry
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
ZacksJohnson & Johnson (JNJ) Stock Moves 0.01%: What You Should Know
In the latest trading session, Johnson & Johnson (JNJ) closed at $154.37, marking a +0.01% move from the previous day.
